Objective
Inflammatory signaling pathways, such as p38 MAPK play a central role in host responses to injury. In our previous studies, topical p38 MAPK inhibitors effectively attenuated inflammatory signaling in a partial-thickness scald burn model, when applied to the burn wound immediately after injury. However, clinically relevant full-thickness scald burn wounds may act as a barrier to topical immune modulators and delayed application of topical p38 MAPK inhibitors may not be effective. In this study, we evaluate the efficacy of topical p38 MAPK inhibition on full-thickness scald burns with immediate and delayed treatment.
Methods
C57/BL6 mice received `Sham' or 30% TBSA full-thickness scald burn injury. After injury, the burn wounds were treated with a topical p38 MAPK inhibitor or vehicle. The treatment group received topical p38 MAPK inhibitor either immediately after burn or 4 hours (delayed) after injury. All animals were sacrificed at 12 or 24 h. Burn wounds underwent histological analyses. Skin and plasma were analyzed by ELISA or RT-qPCR for cytokine expression.
Results
Full-thickness scald burns resulted from immersion in 62°C water for 25 s. Topical p38 MAPK inhibitor attenuated dermal IL-6, MIP-2, and IL-1β expression and plasma IL-6 and MIP-2 cytokine expression. In addition, delayed application of topical p38 MAPK inhibitors significantly reduced dermal and plasma cytokine expression compared to vehicle control.
Conclusion
Topical p38 MAPK inhibitors remain potent in reducing full-thickness burn wound inflammatory signaling, even when treatment is delayed by several hours post injury. Topical application of p38 MAPK inhibitor may be a clinically viable treatment after burn injury.